Publications by authors named "Maria-Jose Calasanz"

Claim this Profile
Q
Quizartinib for Newly Diagnosed -Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.
Pau Montesinos, Rebeca Rodríguez-Veiga, Juan Miguel Bergua, Jesús Lorenzo Algarra Algarra, Carmen Botella, Maria José Calasanz

J Clin Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Quizartinib for Newly Diagnosed -Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.
Pau Montesinos, Rebeca Rodríguez-Veiga, Juan Miguel Bergua, Jesús Lorenzo Algarra Algarra, Carmen Botella, Maria José Calasanz

J Clin Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CEBPA-bZIP Mutations in AML Patients Treated With Non-Intensive Therapy: A Study by the Spanish PETHEMA Registry.
Esther Prados de la Torre, Josefina Serrano, Eva Barragán, Rosa Ayala, María José Calasanz

Hematol Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial.
Juan José Lahuerta, Jesús San-Miguel, Ana Jiménez-Ubieto, Rafael Alonso, Bruno Paiva, María José Calasanz

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment.
Marta Lasa, Carmen Gonzalez, Laura Notarfranchi, Anastasiia Zherniakova, Diego Alignani, Maria Jose Calasanz

Blood· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials.
David F Moreno, Albert Oriol, Javier de la Rubia, Miguel T Hernández, María Belén Iñigo, Maria-Jose Calasanz

Clin Lymphoma Myeloma Leuk· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.
Birna Thorvaldsdottir, Larry Mansouri, Lesley-Ann Sutton, Ferran Nadeu, Manja Meggendorfer, María José Calasanz

Leukemia· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SOX4 in chronic lymphocytic leukaemia: the forgotten transcription factor.
Ricardo García-Muñoz, Jone Alberdi-Ballina, Giovanna Farfan-Quiroga, Eloy F Robles, María José Larráyoz, María José Calasanz

Blood Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma.
Camila Guerrero, Maria-Jose Larrayoz, Irache Erdozain, Noemi Puig, Maria-Teresa Cedena, Maria-Jose Calasanz

Blood Cancer Discov· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic evolution and relapse-associated mutations in adult T-cell acute lymphoblastic leukemia patients treated in PETHEMA trials.
Celia González-Gil, Thaysa Lopes, Mireia Morgades, Francisco Fuster-Tormo, Pau Montesinos, María José Calasanz

Hemasphere· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From Sanger to Oxford Nanopore MinION Technology: The Impact of Third-Generation Sequencing on Genetic Hematological Diagnosis.
María José Larráyoz, Pablo Luri-Martin, Amagoia Mañu, Oihane Churruca, Natalia Gordillo, María José Calasanz

Cancers (Basel)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy.
Andrea Manubens, Bruno Paiva, Norma C Gutiérrez, Manuela Fernandez, Maria-José Calasanz

Hemasphere· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma.
Marta Lasa, Laura Notarfranchi, Cristina Agullo, Carmen Gonzalez, Sergio Castro, Maria Jose Calasanz

J Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial.
Noemí Puig, Cristina Agulló, Teresa Contreras, José-Juan Pérez, Irene Aires, María-José Calasanz

Haematologica· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression profile of Bcl-2 family proteins in newly diagnosed multiple myeloma patients.
Cristina De Ramón, Elizabeta A Rojas, Irena Misiewicz-Krzeminska, Ignacio J Cardona-Benavides, Myriam Cuadrado, María-José Calasanz

Hemasphere· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia.
Catia Simoes, Carmen Gonzalez, François Vergez, Audrey Sarry, Sarah Bertoli, Maria-Jose Calasanz

Blood Neoplasia· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of mutated bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry.
Esther Prados De la Torre, Josefina Serrano, David Martínez-Cuadrón, Laura Torres, Claudia Sargas, María José Calasanz

Haematologica· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epigenetic-based differentiation therapy for Acute Myeloid Leukemia.
Edurne San José-Enériz, Naroa Gimenez-Camino, Obdulia Rabal, Leire Garate, Estibaliz Miranda, María José Calasanz

Nat Commun· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RASping myeloma genomics.
Bruno Paiva, María-José Calasanz

Blood· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
but Not Mutations Are Associated with an Overexpression of Retinoid X Receptor Alpha in Essential Thrombocythemia.
Ana Guijarro-Hernández, Cristina Hurtado, María José Larráyoz, María José Calasanz, José Luis Vizmanos

Cancers (Basel)· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling.
Ignacio J Cardona-Benavides, Irena Misiewicz-Krzeminska, Elizabeta A Rojas, Cristina De Ramón, Antonio Sanz-Solas, María-José Calasanz

Haematologica· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.
Camila Guerrero, Noemi Puig, María-Teresa Cedena, María-José Calasanz, Norma C Gutierrez

Blood· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Catia Simoes, Sara Villar, Beñat Ariceta, Juan-José Garcés, Leire Burgos, Maria-Jose Calasanz

Br J Haematol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highs and lows of t(4;14) in multiple myeloma.
Bruno Paiva, Maria-Jose Calasanz

Blood· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.
Claudia Sargas, Rosa Ayala, María José Larráyoz, María Carmen Chillón, Estrella Carrillo-Cruz, María José Calasanz

Cancers (Basel)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis